NTRA
Price
$399.01
Change
+$3.36 (+0.85%)
Updated
Oct 14, 01:10 PM (EDT)
Capitalization
59.35B
28 days until earnings call
Intraday BUY SELL Signals
XGN
Price
$8.72
Change
+$0.25 (+2.95%)
Updated
Oct 14, 11:23 AM (EDT)
Capitalization
205.43M
33 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NTRA vs XGN

NTRA vs XGN Comparison Chart in %
View a ticker or compare two or three
VS
NTRA vs. XGN commentary
Oct 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTRA is a Hold and XGN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NTRA with price predictions
Oct 13, 2026

Momentum Indicator for NTRA turns negative, indicating new downward trend

NTRA saw its Momentum Indicator move below the 0 level on October 08, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned negative. In 81 of the 100 cases, the stock moved further down in the following days. The odds of a decline are at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NTRA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 24 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.

The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 37 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

NTRA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 55 cases where NTRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

Following a +4.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 241 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 243 of 286 cases where NTRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.

The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.573) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for XGN with price predictions
Oct 13, 2026

XGN in downward trend: price may drop because broke its higher Bollinger Band on September 18, 2026

XGN broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In 35 of the 39 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for XGN moved out of overbought territory on September 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 29 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 31 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 51 cases where XGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on XGN as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.

Following a +7.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 182 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

The Aroon Indicator entered an Uptrend today. In 151 of 179 cases where XGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.807) is normal, around the industry mean (72.578). P/E Ratio (0.000) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

FUNDAMENTALS RATINGS
NTRA vs XGN: Fundamental Ratings
NTRA
XGN
OUTLOOK RATING
1..100
9187
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
31
Undervalued
PROFIT vs RISK RATING
1..100
11100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
3534
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
16n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XGN's Valuation (31) in the null industry is in the same range as NTRA (54) in the Biotechnology industry. This means that XGN’s stock grew similarly to NTRA’s over the last 12 months.

NTRA's Profit vs Risk Rating (11) in the Biotechnology industry is significantly better than the same rating for XGN (100) in the null industry. This means that NTRA’s stock grew significantly faster than XGN’s over the last 12 months.

NTRA's SMR Rating (94) in the Biotechnology industry is in the same range as XGN (99) in the null industry. This means that NTRA’s stock grew similarly to XGN’s over the last 12 months.

XGN's Price Growth Rating (34) in the null industry is in the same range as NTRA (35) in the Biotechnology industry. This means that XGN’s stock grew similarly to NTRA’s over the last 12 months.

XGN's P/E Growth Rating (100) in the null industry is in the same range as NTRA (100) in the Biotechnology industry. This means that XGN’s stock grew similarly to NTRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTRAXGN
RSI
ODDS (%)
Bearish Trend 1 day ago
63%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 14 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
COMPARISON
Comparison
Oct 14, 2026
Stock price -- (NTRA: $395.65 vs. XGN: $8.48)
Brand notoriety: NTRA and XGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NTRA: 69% vs. XGN: 134%
Market capitalization -- NTRA: $59.35B vs. XGN: $205.43M
NTRA [@Medical Specialties] is valued at $59.35B. XGN’s [@Medical Specialties] market capitalization is $205.43M. The market cap for tickers in the [@Medical Specialties] industry ranges from $27 to $4.39T. The average market capitalization across the [@Medical Specialties] industry is $20.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTRA’s FA Score shows that 1 FA rating(s) are green while XGN’s FA Score has 1 green FA rating(s).

  • NTRA’s FA Score: 1 green, 4 red.
  • XGN’s FA Score: 1 green, 4 red.
According to our system of comparison, NTRA is a better buy in the long-term than XGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTRA’s TA Score shows that 3 TA indicator(s) are bullish while XGN’s TA Score has 4 bullish TA indicator(s).

  • NTRA’s TA Score: 3 bullish, 5 bearish.
  • XGN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, XGN is a better buy in the short-term than NTRA.

Price Growth

NTRA (@Medical Specialties) experienced а -1.25% price change this week, while XGN (@Medical Specialties) price change was +3.54% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.75%. For the same industry, the average monthly price growth was +0.48%, and the average quarterly price growth was +35.69%.

Reported Earning Dates

NTRA is expected to report earnings on Nov 11, 2026.

XGN is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Medical Specialties (-2.75% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

View a ticker or compare two or three
NTRA
Daily Signal:
Gain/Loss:
XGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
XMAR43.79-0.02
-0.03%
FT Vest U.S. Equity Enhance & Moderate Buffer ETF - March (XMAR)
IBDU22.69-0.01
-0.04%
iShares iBonds Dec 2029 Term Corporate ETF (IBDU)
NUKX30.99-0.18
-0.59%
Nicholas Nuclear Income ETF
KGRN21.51-0.21
-0.97%
KraneShares MSCI China Clean Technology Index ETF (KGRN)
PJP120.92-2.52
-2.04%
Invesco Pharmaceuticals ETF (PJP)

XGN and

Correlation & Price change

A.I.dvisor tells us that XGN and SHC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XGN and SHC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XGN
1D Price
Change %
XGN100%
+2.79%
SHC - XGN
30%
Poorly correlated
+0.33%
NTRA - XGN
28%
Poorly correlated
-0.53%
QDEL - XGN
26%
Poorly correlated
+6.42%
MXCT - XGN
25%
Poorly correlated
-3.09%
GRAL - XGN
25%
Poorly correlated
+2.17%
More